cyrilzakka/clinical-trials huggingface dataset:
Continuous Intraocular Pressure (IOP) Monitoring in Pigmentary Dispersion Syndrome and Pigmentary Glaucoma Patients

This study monitors the intraocular pressure (IOP) over 4 to 6 hours using the SENSIMED Triggerfish® device and Goldmann Applanation Tonometry (GAT) in pigment dispersion syndrome and pigmentary glaucoma patients. The aim of the study is to detect SENSIMED Triggerfish® output signal peak after induced fluctuation by physical exercise or pupil dilation.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of pigmentary dispersion syndrome or pigmentary glaucoma on both eyes
* IOP of ≥ 15 mmHg
* 18-60 years.
* Patients able to jog continuously for at least 25 minutes
* Phakic eyes
* Patients who accept signing an informed consent approved by the Ethics Committee.

Exclusion Criteria:

* Pigmentary glaucoma already treated with peripheral laser iridotomy (PLI), argon laser peripheral iridoplasty (ALPI), argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) in any eye
* Patients treated with pilocarpine or other mydriatic agent within the last 4 weeks in any eye
* Anti-hypertensive treatment in the 4 weeks preceding the study and throughout the study. Following signature of informed consent, anti-hypertensive treatment will be washed out for 4 weeks prior to study procedures in enrolled patients
* Patients with pseudoexfoliative (PEX) syndrome or PEX glaucoma in any eye
* Patients not able to understand the nature of the research
* Patients under tutorship
* Corneal abnormality
* Subjects with contraindications for wearing contact lenses
* Full frame metal glasses during SENSIMED Triggerfish® monitoring
* History of other ocular surgery except uncomplicated strabismus surgery no later than 3 months prior to study procedures
* Ocular inflammation or infection
* History of cardiac or pulmonary disorder
* Pregnancy and lactation
* Simultaneous participation in other clinical research
Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.

The researchers collect H.pylori-positive patients who need rescue therapy from the outpatient clinic. The subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates and patient compliance of each group.

The researchers collect H.pylori-positive patients who need rescue therapy from the outpatient clinic. If the subject meets the selection criteria but not the exclusion criteria, and signs an informed consent form, the researchers randomized the subjects in groups: subjects received a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. The medication of groups are as follows. 6-8 weeks after the eradication treatment, the subjects will review the 13C-urea breath test, and the researcher records the results.

After all subjects were tested, the eradication rates, adverse reaction rates and patient compliance of each group were calculated.

According to the dose and frequency of tetracycline, it is randomized into a tid treatment group and a qid treatment group. The two groups of bismuth quadruple regimens are the same, as follows:

Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid

Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid

Eligibility Criteria:
Inclusion Criteria:

1. Patients aged 18-70.
2. Patients with H.pylori infection (Positive for rapid urease test or 13C/14C-urea breath test).
3. Patients who have previous failed H. pylori eradication treatment, and ≤ 2 times.

Exclusion Criteria:

1. Patients with serious underlying diseases, such as liver insufficiency (Aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the normal value), renal insufficiency (Cr≥2.0mg/dL or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%.
2. Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial.
3. Patients with active gastrointestinal bleeding.
4. Patients with a history of upper gastrointestinal surgery.
5. Patients allergic to treatment drugs.
6. Patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks
7. Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse
8. Patients who are unwilling or incapable to provide informed consents
SBRT in 4 Fractions for Prostate Cancer

This is a prospective multicentric phase-I-II pilot feasibility study. The main objective is to study early and late side effects of hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam. The schedule will be \[ 4 x 9.5 Gy = 38 Gy \] delivered in 5 alternative days.


Eligibility Criteria:
Inclusion Criteria:

* Age ≤ 85years.
* WHO performance status ≤ 2.
* PSA\>10 and ≤ 20 ng/ml or Gleason Score 7 or T2a-T2c.
* Histologically proven prostate adenocarcinoma
* No pathologic lymph nodes on CT/ MRI scan.
* No distant metastases.
* No previous prostate surgery other than TURP (at least 6 weeks interval before initiation of RT).
* No malignant tumours in the previous 5 years.
* IPSS 0-7.
* Combined HT according to risk factors.
* Informed consent.

Exclusion Criteria:

* Prostate size greater than 60cc.
* Previous TURP less than 6 weeks before radiotherapy.
* Previous prostate surgery other than TURP.
* Diabetes \*.
* Use of anticoagulants drugs \*.
* Chronic inflammatory bowel disease \*.
* Previous pelvic irradiation.
* Inability to obtain written informed consent.
Innovative Training Methods for Frail Elderly in the Training Gain Stage

This study aims to examine long term effects in the training gain stage of the falls management exercise programs (FaME, from Skelton and Dinan) over 10 weeks on physical functional performance after mechanical SR-WBV, dance therapy and strength training intervention in a frail elderly population.

This study is based on the guideline of falls management exercise programs (FaME; from Skelton and Dinan).

The goals:

Skilling up: improvement in neuromuscular control, postural control and strengthening of large muscle groups of the lower extremity.

Training Gain: improvement of functional abilities. Maintaining the Gains: muscle growth, improvement of bone density and multi-sensory exercises.

First, a pilot study was conducted with untrained elderly ("Effects of stochastic resonance therapy on postural control in the elderly population" (KEK Bern: No.228/09, Clinical Trial Registry: NCT01045746). Following, a second pilot study was conducted with frail elderly (Application of Whole-body Vibration With Stochastic Resonance in Frail Elderly: The Effects on Postural Control Clinical Trial Registry: NCT01543243).

It was found that the selected chosen form of recruitment (presentation and advertisement) and the measurements methods are suitable for untrained elderly. But for frail elderly the chosen form of recruitment and the measurement methods are not sufficient.

For this study, adapted measurement parameters for balance, strength and cognition will be used.

The goals of this study:

Evaluate the effects of

* functional lower extremity
* dynamic balance
* reaction time
* mobility
* muscle strength and cognition.

This is a one-group pre-post design study and the participants will be recruited in Canton Bern - Switzerland.

Eligibility Criteria:
Inclusion Criteria:

* RAI (Resident Assessment Instrument) \>0
* live in canton Bern
* in terms of training load be resistant.

Exclusion Criteria:

* acut joint disease, acut thrombosis, acute fractures, acute infections, acute tissue damage, or acute -- surgical scars
* seniors with prosthesis.
* alcoholic
* acute joint disease, activated osteoarthritis, rheumatoid arthritis
* acute inflammation or infection tumors
* fresh surgical wounds
* severe migraine
* epilepsy
* acute severe pain
Assisted Suicide in Switzerland

Background:

Researchers want to learn more about how the Swiss model of assisted suicide works. To do this, they have interviewed 25 Swiss experts. The researchers will draw on research in the fields of ethics, law, and medicine to analyze the transcripts.

Objective:

To describe the practice of assisted suicide in Switzerland and to study how the policy is carried out, how the right-to-die societies work, and the ethical implications of the practice.

Eligibility:

Swiss experts in the field of assisted suicide

Design:

The study includes 25 interviews that have already been conducted. The participants were:

* academics
* doctors and others in medical care
* a government official
* representatives of right-to-die societies.

Researchers will analyze the data using qualitative methods. Two researchers will develop a coding scheme and code the texts and analyze the data.

Switzerland is the only country in the world that enables assisted suicide by lay people, i.e.,

people who are not physicians. All other countries that have adopted aid-in-dying legislation

require that a physician provides this assistance. This project probes the reasons for adopting this policy, and the advantages and the disadvantages of the Swiss model at the end of life. Are the Swiss aid-in-dying volunteers able to provide well-informed assistance to patients in need? Is the Swiss model one to be followed by other nations? The project will focus on the work of the Swiss aid-in-dying societies. The study draws on research in the fields of ethics, law and medicine. Its novelty lies in incorporating different methods of analysis, reflecting on the right to die with dignity within a liberal framework that aims to respect fundamental human rights.

Eligibility Criteria:
* INCLUSION/EXCLUSION:

The study includes 25 interviews with Swiss experts that have been conducted.

* Gender: Men 14, Women 11
* Backgrounds of interviewees: Academics 14, Physicians and other medical care 6, Right to die associations 4, Government official 1
* Race and ethnicity: All white Swiss.
* Age range: Unknown, but all are adults.
* No vulnerable populations.
Leukemia Cell Cultures for Research of New Anti-Cancer Therapies

The main objective of this project is not only a better understanding of the human leukemic disease but also to find new anti-leukemic or improve existing ones. This study has, the following aims:

* To analyze the genetic and epigenetic regulation of the retinoic acid induced cascade which leads to the expression of TRAIL in blood cells of patients with acute leukemia. This study will be complemented by the analysis of global gene expression (DNA chips) and of the DNA methylation state, and by chromatin immunoprecipitation experiences.
* To determine the efficiency of inhibitors of enzymes responsible for the modification of chromatin (existing and new developments within the European consortium EPITRON coordinated by Dr Gronemeyer) as inducers of differentiation and / or apoptosis of leukemic blasts.
* To explore Ikaros genic and functional abnormalities (genomic deletions, mutations, abnormal transcripts and proteins) in acute leukemia. The aim is to determine if these abnormalities may play a prognosis role.


Eligibility Criteria:
Inclusion Criteria:

* Patients with suspected de novo or secondary or relapsed acute leukemia, requiring complementary blood test and bone marrow analysis
* Patients older or equal than 28 days
* Informed consent signed

Exclusion Criteria:

* Pregnancy
* Breastfeeding
Conversion to Monotherapy Study With Keppra XR for Partial Seizures

The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.


Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects 12 to 75 years of age.
* Subjects must have inadequately controlled partial onset epilepsy.
* Subjects must be experiencing 2 to 40 seizures per 4-week period while being maintained on one or two standard AED(s)

Exclusion Criteria:

* A history of status epilepticus in the 6 months preceding randomization.
* Significant medical, psychiatric or neurological illness.
* Intake of benzodiazepines on more than an occasional basis
* History of previous treatment with levetiracetam or sensitivity to levetiracetam.
Randomized Comparison of xiEnce and visioN Coronary Stents in the sAme muLtivessel Patient With Chronic kiDnEy diSease

Percutaneous coronary intervention (PCI) with bare metal stent (BMS) in patients with renal insufficiency has shown unsatisfactory results. Indeed, drug-eluting stents (DES) might reduce the incidence of restenosis and therefore of target lesion revascularization procedures in these patients.

We therefore designed a prospective, randomized, multicenter, not-sponsored study to directly compare the efficacy in the prevention of clinical restenosis of everolimus-eluting stent (Xience V) and bare-metal stent (Vision) (both 2nd-generation DES and BMS, respectively), both implanted in the same patient with multivessel disease and renal insufficiency in order to obviate for the multiple and unpredictable characteristics of this high-risk population.


Eligibility Criteria:
Inclusion Criteria:

* chronic renal insufficiency (creatinine clearance \<60 ml/min, in dialysis patients included) with at least two significant (\>70%) coronary lesions in two major coronary vessels.

Exclusion Criteria:

* Age \>85 years
* left main coronary artery disease
* saphenous vein graft disease
* ST-elevation MI (\<3 days)
* coronary vessel diameter \<2.5 or \> 4 mm
* contraindication to long-term double antiplatelet therapy
* CABG indication by consensus (cardiovascular team)
* severe valvular heart disease
* informed consent not obtained
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)

Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Latrunculin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Latrunculin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,


Eligibility Criteria:
Inclusion Criteria:

* ICSI participants

Exclusion Criteria:

-
The Effect of 10 cm Catheter Mount on Malfunction of Capnometers Under the Conditions of Water

Capnometer has been used to assess the success of intubation and the quality of cardiopulmonary resuscitation. However, capnometers can malfunction under the conditions such as pulmonary edema and hemorrhage due to the vulnerability of capnometers for water. Investigators hypothesized that the use of 10cm catheter mount will reduce the malfunction of capnometers under the conditions of water.


Eligibility Criteria:
Inclusion Criteria:

* Healthy adults without underlying disease

Exclusion Criteria:

* Lung and heart disease
* Drinking carbonated beverages
Low Tidal Volume Ventilation With Hyperoxia Avoidance During Cardiopulmonary Bypass (The FOCUS Trial)

This is a multi-institutional study (CCF, UPMC, OSU) evaluating different ventilation strategies during cardiopulmonary bypass on mortality and postoperative pulmonary complications, with sub-study investigating 8-iso-prostaglandin F2a and sRAGE levels.

The investigators will evaluate the effect of low tidal volume with varying FiO2 fractions during cardiopulmonary bypass on postoperative mortality and pulmonary complications. This will be a prospective, pragmatic, cluster randomized trial including all eligible adult cardiac surgical patients requiring cardiopulmonary bypass. Each week, all operating rooms will be randomized to one of three possible ventilation strategies during the period of cardiopulmonary bypass: 1) continuous low tidal volume ventilation with inspired oxygen fraction at 1.0, 2) continuous low tidal volume ventilation with inspired oxygen fraction at 0.21, and 3) no ventilation (apnea). The investigators will anticipate increase in plasma sRAGE and 8-iso-prostaglandin F2a levels in all three groups of patients during CPB with the highest levels immediately after cross-clamp release. The investigators will anticipate significant difference with at least 25% lower sRAGE levels in this group. The sub-study will also provide preliminary data on the behavior of the 8-iso-prostaglandin F2a which will be useful in further investigation of other targeted interventions to reduce ischemia-reperfusion injury to the lung during routine cardiac surgical operations.

Eligibility Criteria:
Inclusion Criteria:

* \>18 years of age
* Male and female patients undergoing elective cardiac surgeries requiring cardiopulmonary bypass.

Exclusion Criteria:

Emergency surgeries, surgeries requiring lung isolation and one-lung ventilation (OLV), heart or lung transplants, and mechanical circulatory support device implantation pulmonary thrombendarterectomies.

* Surgeries requiring one-lung ventilation will be excluded because of the inability to employ study intervention and the differential treatment of the lungs likely confounding any potential effect from the planned intervention.
* Lung transplant surgeries will be excluded for similar reasons as well as other confounding effects affecting the primary composite outcome.
* Heart transplants and mechanical circulatory support device implantation surgeries will be excluded because these patients already receive intervention as part of the institutional protocol at the primary study site.
Recipe for Heart Health

The overall objectives of this project are to compare clinical parameters in moderate risk Atherosclerotic Cardiovascular Disease (ASCVD) patients following a Whole Food Plant Based (WFPB) diet containing a high (4 TB) compared to a low (\<1 tsp) amount of raw extra virgin olive oil.

Up to sixty-eight primary prevention outpatient adults with intermediate to high ASCVD risk factors will be randomized in a crossover fashion to follow a WFPB diet without animal products that is either high (4 tablespoons) or low (\< \~1 teaspoon) in raw extra virgin olive oil. After confirming eligibility and patients provide consent, the research team will randomize the participant at the baseline visit. The baseline visit and run-in visit 1 will follow as described below. With the intent of recruiting cohorts of ten, a group of participants will subsequently begin the first Whole Food Plant Based culinary diet intervention for four weeks, followed by a one-week (+ 3 days) washout period before switching to the opposite oil diet for an additional four weeks. During each of the 4-week interventions, participants will attend weekly cooking sessions that align with the dietary intervention with a registered dietitian. Patients will be asked to maintain levels of physical activity through the duration of the study. Data will be collected at the patient's cardiology visits before and after each diet intervention for a total of four in-person visits excluding the screening visit.

Eligibility Criteria:
Inclusion Criteria:

-Adult patients with borderline to high risk for ASCVD

Exclusion Criteria:

-Adult patients with known cardiovascular disease
Genetic Polymorphisms, Steatosis and Diabetes

* Our research hypothesis is to show that a certain number of genetic polymorphisms of the proteins involved in glucose, lipid and adipocyte metabolism are factors that favour the development of steatosis in patients with Type 2 diabetes.
* We also wish to evaluate more thoroughly lipid anomalies associated with the presence of steatosis, notably with regard to monocyte expression of LDL receptors. We hypothesize that hepatic steatosis is accompanied by activation of transcription factors involved in lipogenesis, notably SREBP factors. The activation of these factors could cause an increase in the expression of LDL receptors, leading to increased LDL catabolism.
* Chronological description of the study During an outpatient consultation at the endocrinology department, diabetic patients, programmed to undergo an examination to assess their diabetes will be invited to participate in the study. Once written informed consent has been provided and clinical data has been recorded, patients with type 1 or type 2 diabetes will have standard biological examination, which is systematically done in such patients (Fasting glycemia, HBA1c, aspartate aminotransferase, alanine amino transferase, Gammaglutamyl-transferases, PAL, bilirubin, blood proteins, albuminemia, Total Cholesterol total, HDL cholesterol, triglycerides, Sedimentation Rate, C-reactive protein, fibrinogen).

As well as the systematic biological tests, 3 additional tubes will be taken to screen for genetic polymorphism in 3 proteins (Microsomal Transfer Protein, Adiponectin receptor - 1, Apolipoprotein A - II).

IN addition, magnetic resonance imaging and magnetic resonance spectroscopy will be done to look for the presence of liver steatosis and to measure carotid intima-media thickness.


Eligibility Criteria:
Inclusion Criteria:

Inclusion criteria Type-2 diabetics:

* Type 2 diabetes
* HbA1C\>6.5%
* 27\<BMI\<55

Inclusion criteria Type-1 diabetics:

* Type 1 diabetes
* BMI\<55 Diagnosis of type-1 diabetes based on the clinical history of the patient and/or the presence of anti-glutamate decarboxylase auto antibodies and/or a plasma level of C peptide below 0,5 ng/l.

Inclusion criteria healthy volunteers:

* Non diabetic
* Alcohol consumption \< 2 glasses per day
* Without hyperglycemic treatment (corticoids, ...)
* Without liver disease (cirrhosis, hepatitis, ...)

Exclusion Criteria:

* Pacemaker
* Daily alcohol consumption above 4 glasses per day
* Patients treated with Glitazones during the 3 months preceding inclusion
* Presence of implants
* Claustrophobia
* Patient \< 18 years
* Patient under guardianship or not intellectually independent
* Pregnancy
Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)

This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma.

The complete histological response will be assessed.


Eligibility Criteria:
Inclusion Criteria:

* Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer \[AJCC\] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient\&#39;s refusal to be operated.
* Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed

Exclusion Criteria:

* Uveal melanoma
Protocolized Initiation of Clonidine to Prevent Dexmedetomidine Withdrawal

The purpose of this study is to determine if the protocolized use of clonidine will reduce dexmedetomidine withdrawal symptoms, reduce PICU length of stay, and reduce costs related to sedation during hospital admission.


Eligibility Criteria:
Inclusion Criteria:

* Dexmedetomidine infusion for greater than or equal to 72 hours

Exclusion Criteria:

* Admission for head trauma
* Psychiatric history
* Use of alpha-2 agonist medications at home
* Death while on dexmedetomidine